AR035312A1 - HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents
HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCTInfo
- Publication number
- AR035312A1 AR035312A1 ARP000100327A ARP000100327A AR035312A1 AR 035312 A1 AR035312 A1 AR 035312A1 AR P000100327 A ARP000100327 A AR P000100327A AR P000100327 A ARP000100327 A AR P000100327A AR 035312 A1 AR035312 A1 AR 035312A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroaryl
- aryl
- alkyl
- cycloalkyl
- acid compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de ácido hidroxámico que contienen alquinilo caracterizados porque comprenden un compuesto que tiene la fórmula (1) en la cual R1 es hidrogeno, arilo, heteroarilo, alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-6, o cicloheteralquilo de C4-8; R2 y R3 son cada uno independientemente hidrógeno, alquilo de C1-6, -CN, o -CCH; R7 es hidrógeno, arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo de C1-6, alquenilo de C2-6, alquinilo de C1-6, cicloalquilo de C3-6, -C(O)-R1, -SO2-R1, -C(O)-NHR1, -C(O)NR5R6, -C(O)R1NR5R6, -C(O)-OR1, -C(NH)-NH2, R8, R9, R10 y R11 son cada uno independientemente, hidrógeno, arilo o heteroarilo, cicloalquilo de C3-6, cicloheteroalquilo C4-8, alquilo de C1-18, alquenilo de C2-18, alquinilo de C2-18, con la condición de que uno de los pares R8, R9, R9 y R10 o R10 y R11 conjuntamente con el átomo o átomos de carbono a los cuales están unidos forman un anillo cicloalquilo de C3-6, o un anillo cicloheteroarilquilo C4-8; R12 es hidrógeno, arilo o heteroarilo, cicloalquilo de C3-6, cicloheteroalquilo C4-8, o alquilo de C1-6; A es O, S, SO, SO2, NR7 o CH2; X es O, S, SO, SO2, NR7 o CH2; Y es arilo o heteroarilo, con la condición de que A y X no están unidos a los átomos adyacentes de Y; y n es 0-2; o una sal farmacéuticamente aceptable del mismo.Alkynyl-containing hydroxamic acid compounds characterized in that they comprise a compound having the formula (1) in which R 1 is hydrogen, aryl, heteroaryl, C 1-8 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl of C3-6, or C4-8 cycloheteralkyl; R2 and R3 are each independently hydrogen, C1-6 alkyl, -CN, or -CCH; R7 is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkynyl, C3-6 cycloalkyl, -C (O) -R1, -SO2-R1, - C (O) -NHR1, -C (O) NR5R6, -C (O) R1NR5R6, -C (O) -OR1, -C (NH) -NH2, R8, R9, R10 and R11 are each independently, hydrogen , aryl or heteroaryl, C3-6 cycloalkyl, C4-8 cycloheteroalkyl, C1-18 alkyl, C2-18 alkenyl, C2-18 alkynyl, provided that one of the pairs R8, R9, R9 and R10 or R10 and R11 together with the carbon atom or atoms to which they are attached form a C3-6 cycloalkyl ring, or a C4-8 cycloheteroaryl ring; R12 is hydrogen, aryl or heteroaryl, C3-6 cycloalkyl, C4-8 cycloheteroalkyl, or C1-6 alkyl; A is O, S, SO, SO2, NR7 or CH2; X is O, S, SO, SO2, NR7 or CH2; Y is aryl or heteroaryl, with the proviso that A and X are not attached to the adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23803899A | 1999-01-27 | 1999-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035312A1 true AR035312A1 (en) | 2004-05-12 |
Family
ID=22896246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100327A AR035312A1 (en) | 1999-01-27 | 2000-01-26 | HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
Country Status (13)
Country | Link |
---|---|
JP (1) | JP2002535390A (en) |
KR (1) | KR20010101732A (en) |
AR (1) | AR035312A1 (en) |
AT (1) | ATE309986T1 (en) |
AU (1) | AU769418B2 (en) |
CA (1) | CA2356313A1 (en) |
CZ (1) | CZ20012711A3 (en) |
DE (1) | DE60024056D1 (en) |
EA (1) | EA200100806A1 (en) |
HU (1) | HUP0200223A3 (en) |
IL (1) | IL144345A0 (en) |
NZ (1) | NZ512566A (en) |
ZA (1) | ZA200105222B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060058350A1 (en) * | 2002-12-26 | 2006-03-16 | Carna Biosciences, Inc. | Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient |
WO2008005268A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
CN102046612A (en) * | 2008-06-02 | 2011-05-04 | 希普拉有限公司 | Processes for the synthesis of levocetirizine and intermediates for use therein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0970046T3 (en) * | 1997-02-27 | 2004-04-13 | Wyeth Corp | N-Hydroxy-2- (alkyl, aryl or heteroarylsulfanyl, sulfinyl or sulfonyl) -3-substituted alkyl or heteroaryl amides as matrix metalloproteinase inhibitors |
HUP0101837A3 (en) * | 1998-02-19 | 2001-11-28 | American Cyanamid Co Madison | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
-
2000
- 2000-01-26 AR ARP000100327A patent/AR035312A1/en not_active Application Discontinuation
- 2000-01-27 KR KR1020017009432A patent/KR20010101732A/en not_active Application Discontinuation
- 2000-01-27 IL IL14434500A patent/IL144345A0/en unknown
- 2000-01-27 CA CA002356313A patent/CA2356313A1/en not_active Abandoned
- 2000-01-27 NZ NZ512566A patent/NZ512566A/en unknown
- 2000-01-27 DE DE60024056T patent/DE60024056D1/en not_active Expired - Lifetime
- 2000-01-27 EA EA200100806A patent/EA200100806A1/en unknown
- 2000-01-27 CZ CZ20012711A patent/CZ20012711A3/en unknown
- 2000-01-27 JP JP2000595979A patent/JP2002535390A/en active Pending
- 2000-01-27 AU AU26305/00A patent/AU769418B2/en not_active Ceased
- 2000-01-27 AT AT00904569T patent/ATE309986T1/en not_active IP Right Cessation
- 2000-01-27 HU HU0200223A patent/HUP0200223A3/en unknown
-
2001
- 2001-06-25 ZA ZA200105222A patent/ZA200105222B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA200100806A1 (en) | 2002-08-29 |
IL144345A0 (en) | 2002-05-23 |
ZA200105222B (en) | 2002-09-25 |
AU769418B2 (en) | 2004-01-29 |
AU2630500A (en) | 2000-08-18 |
NZ512566A (en) | 2004-02-27 |
CA2356313A1 (en) | 2000-08-03 |
CZ20012711A3 (en) | 2002-05-15 |
HUP0200223A3 (en) | 2002-12-28 |
DE60024056D1 (en) | 2005-12-22 |
JP2002535390A (en) | 2002-10-22 |
HUP0200223A2 (en) | 2002-06-29 |
ATE309986T1 (en) | 2005-12-15 |
KR20010101732A (en) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035313A1 (en) | ACETILENIC TACE INHIBITORS OF HYDROXAMIC ACID OF SULFONAMIDE BASED ON ALFA-AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES. | |
AR011093A1 (en) | COMPOUNDS DERIVED FROM SULFONIL UREA, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PROCEDURE FOR ITS USE. | |
PE20070218A1 (en) | AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE | |
AR082152A1 (en) | DERIVATIVES OF N- (METILSULFONIL) BENZAMIDE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF NAV1.7 | |
AR064608A1 (en) | SUBSTITUTED PIRAZOLO-QUINAZOLINA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. PROCESS FOR THE PREPARATION AND USE OF THE SAME AS ANTICANCER AGENTS. | |
ES2137998T3 (en) | NEW AMINO ACID DERIVATIVES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINED IN THESE COMPOUNDS. | |
AR124662A2 (en) | IMMUNOSUPPRESSANT FORMULATIONS | |
AR038235A1 (en) | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEIVER | |
AR050261A2 (en) | AMINO ACIDS AFFECTED BY THE ALFA-2-DELTA PROTEIN AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT | |
AR069510A1 (en) | ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10 | |
AR058073A1 (en) | IMIDAZOL 5-IL-PYRIMIDINE DERIVATIVES, OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES | |
AR083849A1 (en) | ESPIRO-OXINDOL MDM2 ANTAGONISTS | |
CO5690588A2 (en) | DERIVATIVES OF 4-TETRAZOLILO-4 PHENYLPIPERIDINE FOR PAIN TREATMENT | |
AR035311A1 (en) | HYDROXAMIC ACID DERIVATIVES CONTAINING ALQUINYL, AS INHIBITORS OF THE METALLOPROTEINAS OF MATRIX AND THE TACE, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
ECSP034475A (en) | DERIVATIVES OF 4-PHENYL-PIRIDIN AS ANTAGONISTS OF THE NEUROQUININE RECEIVER-1 | |
ES2566973T9 (en) | Use of SNS-595 to treat leukemia | |
AR048834A1 (en) | COMPOUNDS DERIVED FROM PIPERIDINE OR TROPANE; METHODS FOR PREPARATION; PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CHEMIOQUINE-MEDIUMED DISEASES (CCR5) | |
ECSP22012347A (en) | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | |
AR040048A1 (en) | DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND INDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6 | |
AR037681A1 (en) | ADENOSINE A2A RECEIVING ANTAGONISTS OF 5-AMINO- [1,2,4] -BICYCLIC TRIAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, THE USE OF THE SAME, ONLY OR IN COMBINATION OF THE COMPOUNDS AND OTHER AGENTS FOR THE PREPARATION OF MEDICINES UTI THE TREATMENT OF PARKINSON'S DISEASE AND A | |
AR029373A1 (en) | METHOD FOR THE TREATMENT OF MIGRANES, USING SELECTIVE ANTAGONIST COMPOUNDS OF THE IGLUR5 RECEPTORS, USE OF SUCH SELECTIVE ANTAGONIST COMPOUNDS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF MIGRANES AND SAVINGS COMPOSED | |
ECSP045503A (en) | DERIVATIVES OF 1 - [(INDOL-3-IL) CARBONIL] PIPERAZINA | |
AR054109A1 (en) | DERIVATIVES OF 2-METHYL-4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF INFERTILITY | |
AR012436A1 (en) | 4-AMINOPIRIDE [2,3-D] PIRIMIDINE 5,7-DISSTITUTED COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, THE USE OF THE SAME FOR LAMANUFACTURE OF MEDICINES, A PROCEDURE FOR THEIR PREPARATION. | |
AR046753A1 (en) | BENZOXAZINE DERIVATIVES AND USES OF THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |